Abstract:

BACKGROUND: Zona pellucida 3 peptide administered orally can prevent and treat the autoimmune premature ovarian failure. As the direct application is not very good, therefore, selecting the appropriate drug carrier system has become the basis for further research.
OBJECTIVE: To prepare zona pellucida 3 peptides-trimethyl chitosan microspheres, and to study their application in premature ovarian failure
METHODS: Zona pellucida 3 peptides-trimethyl chitosan microspheres were prepared by ionic cross-linking. Morphology of microspheres was examined by scanning electron microscope, and the microspheres size, encapsulation efficiency, drug loading rate and release rate were examined. The zona pellucida 3 peptides-trimethyl chitosan microspheres, PBS, zona pellucida 3 peptides and trimethyl chitosan microspheres were used respectively for the treatment of mice with premature ovarian failure.
RESULTS AND CONCLUSION: The morphology of zona pellucida 3 peptides-trimethyl chitosan microspheres was regular. The average microsphere size was 280.5 nm, encapsulation efficiency was 69.20%, and drug loading rate was 14.83%. The in vitro release rate of zona pellucida 3 peptides-trimethyl chitosan microspheres was gradually increased with time passing without burst release phenomenon. The positive rate of anti-zona pellucida 3 peptides in the peripheral blood of premature ovarian failure mice in zona pellucida 3 peptides-trimethyl chitosan microspheres group was significantly lower than that in the other three groups (P < 0.05). It indicates that zona pellucida 3 peptides-trimethyl chitosan microspheres can significantly reduce the positive rate of anti-zona pellucida 3 peptides in the peripheral blood of premature ovarian failure mice.